Inclusion Criteria:

- Patients >18 years affected by advanced or metastatic HCC previously treated with no
more than one systemic therapeutic regimen

- Histologically confirmed HCC not amenable to curative surgery

- Child-Pugh scale class A

- ECOG Performance status 0 - 1

- Patients in progression disease at study entry CT documented

- Adequate baseline bone marrow, hepatic and renal function, defined as follows:

- Neutrophils > 1.5 x 10^9/L and platelets > 100 x 10^9/L

- Bilirubin < 2 x ULN

- Transaminases < 3 x ULN

- Absence of any conditions in which hypervolaemia and its consequences (e.g. increased
stroke volume, elevated blood pressure) or haemodilution could represent a risk for
the patient (reference appendix "Technical data sheet human albumin")

- Normal cardiac function and absence of uncontrolled hypertension

- Patients must give written informed consent

Exclusion criteria:

- Decompensated cirrhosis (Child-Pugh score >7)

- Concurrent anticancer therapy

- Patients may not receive any other investigational agents while on study

- Clinical signs of CNS involvement

- Patients with active or uncontrolled systemic disease/infections or with serious
illness or medical conditions, which is incompatible with the protocol

- Known hypersensitivity/allergic reaction to human albumin preparations or to any of
the excipients

- Any psychological, familial, sociological or geographical condition potentially
hampering compliance with the study protocol

- Pregnancy or lactation. Patients - both males and females - with reproductive
potential (i.e. menopausal for less than 1-year and not surgically sterilized) must
practice effective contraceptive measures throughout the study. Women of childbearing
potential must provide a negative pregnancy test (serum or urine) within 14 days
prior to registration